| 韩雪纯,张 烨,栾军军,冉孟萍,周 华.血管紧张素受体阻断剂联合冬虫夏草对肾小球肾炎临床疗效观察[J].现代生物医学进展英文版,2020,(15):2853-2857. |
| 血管紧张素受体阻断剂联合冬虫夏草对肾小球肾炎临床疗效观察 |
| A Clinical Observation of the Effect of ARB Combining with Cordyceps Sinensis during Therapy Towards Glomerulonephritis |
| Received:December 28, 2019 Revised:January 23, 2020 |
| DOI：10.13241/j.cnki.pmb.2020.15.010 |
| 中文关键词: 血管紧张素受体阻断剂 冬虫夏草 肾小球肾炎 尿微量白蛋白 尿?琢1微量球蛋白 |
| 英文关键词: ARB Caterpillar fungus Glomerulonephritis Microalbuminuria ?琢1 microglobulin |
| 基金项目:国家自然科学基金面上项目（81770698；81370835）；辽宁省重点研发指导计划项目（2019JH8/10300009）；辽宁省攀登学者资助项目（2013222） |
| Author Name | Affiliation | E-mail | | HAN Xue-chun | Department of nephrology, The Affiliated Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110000, China | hansally_cmu@163.com | | ZHANG Ye | Hebei General Hospital, Shijiazhuang, Hebei, 050000, China | | | LUAN Jun-jun | Department of nephrology, The Affiliated Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110000, China | | | RAN Meng-ping | Department of nephrology, The Affiliated Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110000, China | | | ZHOU Hua | Department of nephrology, The Affiliated Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110000, China | |
|
| Hits: 799 |
| Download times: 426 |
| 中文摘要: |
| 摘要 目的：探讨血管紧张素受体阻断剂联合冬虫夏草对肾小球肾炎的临床疗效。方法：选取2011年1月至2015年3月期间我院收治的340名尿检符合蛋白尿或血尿的患者作为研究资料，按治疗方式将研究对象分为A组（单纯百令组）、B组（奥美沙坦组）、C组（除去奥美沙坦外的其他ARB组）、D组（所有ARB组）、E组（奥美沙坦联合百令组）、F组（除去奥美沙坦外的其他ARB联合百令组）、G组（所有ARB联合百令组），于服药1、2、3个月跟踪随访尿微量白蛋白、尿a1微量球蛋白、血尿、血生化等指标的变化。结果：与单纯百令组相比，单独应用ARB组或ARB联合百令胶囊组在降低肾小球性蛋白尿方面显示出了良好的疗效(P<0.05)；在降低肾小管蛋白尿方面，单独应用ARB仅在1月组显示出明显效果，而ARB联合百令治疗则在1-3个月均显示出持续的缓解(P<0.05)；无论单用ARB还是ARB联合百令对于血生化指标的显著影响仅体现在治疗1个月内(P<0.05)。结论：常规应用ARB类药物治疗同时，加用冬虫夏草治疗，可以更加有效的降低蛋白尿，保护肾小管功能，对于改善患者病情及延缓疾病发展具有重要意义。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical effect of ARB combining with cordyceps sinensis during therapy towards glomerulonephritis. Methods: From January 2011 to March 2015, 340 cases of proteinuria or hematuria patients in our hospital were selected as the research data. According to different treatments, subjects can be divided into group A (bailing capsule); group B (olmesartan); group C (other ARBs except for olmesartan); group D (all ARBs); group E (olmesartan + bailing capsule); group F (other ARBs except for olmesartan + bailing capsule); group G (all ARBs + bailing capsule). Urinary microalbumin, a1 microglobulin, hematuria, serological characteristics were followed up for 1, 2 and 3 months after taking medicine. Results: Contrast with bailing group, ARBs or ARBs + bailing capsule showed excellent efficacy in reducing glomerular proteinuria (P <0.05). ARBs showed significant efficacy in reducing tubular-proteinuria only within 1 month of treatment, whereas ARBs + bailing revealed sustained remission in 1-3 month (P <0.05). The significant influence on serological characteristics in either ARBs or ARBs + bailing was only reflected within 1 month of treatment (P <0.05). Conclusion: The routine application of ARB + cordyceps sinensis therapy can reduce proteinuria more effective as well as protect renal tubular function, which has significance in improving patients' conditions and delaying the development of disease. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
